I recommended a buy rating for Health Catalyst (NASDAQ: HCAT ) when I wrote about it in March, as I was confident that HCAT could achieve its FY28 targets by executing growth strategies that have a stronger I consider an investment ideal if it performs its core business in a sector projected to experience structural (organic) growth in excess of GDP growth over the next 5-10 years; profits from sustainable competitive advantages that translate into attractive unit economics; In the hands of competent, ethic ...